New cocktail aims to keep High-Risk myeloma at bay
NCT ID NCT05208307
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing whether a combination of belantamab mafodotin, pomalidomide, and dexamethasone can help prevent high-risk myeloma from returning after a stem cell transplant. About 34 patients who have already responded to transplant will receive the drug combo as maintenance therapy. The goal is to see how many achieve a complete response and how safe the treatment is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin, pomalidomide, and dexamethasone
What this could lead to
If successful, this combination could become a new maintenance option to help keep high-risk myeloma in remission longer after a stem cell transplant.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply to all patients. The drugs can cause side effects like eye problems, low blood counts, and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••